Dosing Considerations for Olaparib

Standard Dosing and Bioequivalence

• The National Comprehensive Cancer Network recommends a standard dose of olaparib tablets of 300 mg twice daily for patients with metastatic castration-resistant prostate cancer (mCRPC) with HRR gene mutations who have received prior androgen receptor-directed therapy 1, 2
• The National Comprehensive Cancer Network suggests close monitoring with complete blood counts and hepatic/renal function, along with transfusion support and/or dose reductions as needed for severe anemia, is recommended during olaparib therapy 1, 2
• Monitoring of complete blood counts every 2-4 weeks in patients with significant cytopenias is advised 1
• Weekly blood count monitoring during the first 4-6 weeks, then every 2 weeks or monthly until month 3, then every 3 months thereafter, is recommended 1